Multiple Myeloma Articles

FDA Approval Sought for Frontline Daratumumab in Myeloma
A supplemental biologics license application has been submitted to the FDA for daratumumab for use in combination with bortezomib, melphalan and prednisone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation.
FDA Grants BCMA CAR T-Cell Therapy Breakthrough Designation in Myeloma
The FDA has granted the the anti–B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapy bb2121 a breakthrough therapy designation for previously treated patients with relapsed/refractory multiple myeloma.
Better Outcomes in High-Risk Multiple Myeloma
Because genetic abnormalities play a role in multiple myeloma, it is important to understand these better to improve outcomes, particularly for high-risk patients, said Shaji K. Kumar, MD. 
Optimal Combinations, Sequences Being Explored in Multiple Myeloma
Adam Waxman, MD, discusses emerging regimens for patients with multiple myeloma.
Triplet Regimens, Maintenance Therapy New Standards for Multiple Myeloma
Alfred L. Garfall, MD, MS, discussed the treatment and management of patients with multiple myeloma, with a focus on maintenance therapy, CAR T-cell therapy, and the role of transplant.
Personalized Medicine Moving to Forefront of Hematologic Malignancies
Edward A. Stadtmauer, MD, sheds light on the future of chimeric antigen receptor T-cell therapy, systemic therapeutic advances in the field of acute myeloid leukemia, and remaining challenges in the multiple myeloma paradigm.
FDA Grants BCMA Antibody-Drug Conjugate Breakthrough Status for Myeloma
The FDA has granted GSK2857916 a breakthrough therapy designation for patients with relapsed/refractory multiple myeloma.
Expert Sheds Light on Role of Combinations, Transplant in Myeloma
Jayesh Mehta, MD, discusses combination therapies in multiple myeloma, as well as the continued importance of stem cell transplant.
Carfilzomib Effective in Myeloma at Less Frequent, Higher Dose
Higher-dose, once-weekly carfilzomib (Kyprolis) demonstrated superior efficacy for patients with relapsed/refractory multiple myeloma compared with a lower-dose, twice-weekly regimen.
Lenalidomide Maintenance Post-ASCT Improves Survival in Myeloma
Maintenance therapy with lenalidomide following autologous stem-cell transplantation conferred a survival benefit for patients with newly diagnosed multiple myeloma.
Publication Bottom Border
Border Publication